118 related articles for article (PubMed ID: 15015576)
1. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
Van Laar ES; Roth S; Weitman S; MacDonald JR; Waters SJ
Anticancer Res; 2004; 24(1):59-65. PubMed ID: 15015576
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Van Laar ES; Weitman S; MacDonald JR; Waters SJ
Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
[TBL] [Abstract][Full Text] [Related]
3. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
4. Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Invest New Drugs; 2008 Oct; 26(5):407-15. PubMed ID: 18227973
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
[TBL] [Abstract][Full Text] [Related]
8. Irofulven (6-hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases.
Wang W; Waters SJ; MacDonald JR; Roth C; Shentu S; Freeman J; Von Hoff DD; Miller AR
Anticancer Res; 2002; 22(2A):559-64. PubMed ID: 12014623
[TBL] [Abstract][Full Text] [Related]
9. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
10. MGI 114: augmentation of antitumor activity when combined with topotecan.
Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts.
Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843
[TBL] [Abstract][Full Text] [Related]
13. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
14. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Yeo D; Huynh N; Beutler JA; Christophi C; Shulkes A; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2014 May; 346(2):264-72. PubMed ID: 24491405
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
Montano R; Thompson R; Chung I; Hou H; Khan N; Eastman A
BMC Cancer; 2013 Dec; 13():604. PubMed ID: 24359526
[TBL] [Abstract][Full Text] [Related]
16. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells.
Wang W; Waters SJ; MacDonald JR; Von Hoff DD; Strodel WE; Miller AR
Anticancer Res; 2001; 21(3B):1789-94. PubMed ID: 11497260
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer.
Ahn DW; Seo JK; Lee SH; Hwang JH; Lee JK; Ryu JK; Kim YT; Yoon YB
Pancreas; 2012 Oct; 41(7):1048-57. PubMed ID: 22513291
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
Staake MD; Kashinatham A; McMorris TC; Estes LA; Kelner MJ
Bioorg Med Chem Lett; 2016 Apr; 26(7):1836-8. PubMed ID: 26922141
[TBL] [Abstract][Full Text] [Related]
19. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
Kazim S; Malafa MP; Coppola D; Husain K; Zibadi S; Kashyap T; Crochiere M; Landesman Y; Rashal T; Sullivan DM; Mahipal A
Mol Cancer Ther; 2015 Jul; 14(7):1570-81. PubMed ID: 25934708
[TBL] [Abstract][Full Text] [Related]
20. ATM-dependent CHK2 activation induced by anticancer agent, irofulven.
Wang J; Wiltshire T; Wang Y; Mikell C; Burks J; Cunningham C; Van Laar ES; Waters SJ; Reed E; Wang W
J Biol Chem; 2004 Sep; 279(38):39584-92. PubMed ID: 15269203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]